Exegenesis Bio, Modalis sign research deal for Duchenne therapy

Exegenesis Bio and Modalis Therapeutics have entered into a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for DMD. Under the agreement, Modalis will be granted rights to utilise EMC181 in the development of MDL-201. EMC181 aims to address DMD by activating utrophin in muscle using CRISPR-GNDM. Credit: MY STOCKERS / Shutterstock.com. Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD). The agreement involves the use of Modalis’ CRISPR-GNDM (Guide Nucleotide-Directed Modulation) technology in combination with Exegenesis Bio’s engineered muscle-tropic adeno-associated virus…

Source: Pharmaceutical Technology